Guardant Health, Inc. (NASDAQ:GH) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC lowered its stake in Guardant Health, Inc. (NASDAQ:GH) by 43.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 25,534 shares of the company’s stock after selling 19,309 shares during the quarter. SG Americas Securities LLC’s holdings in Guardant Health were worth $780,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. JNBA Financial Advisors purchased a new stake in Guardant Health during the third quarter valued at about $26,000. Ashton Thomas Securities LLC purchased a new stake in Guardant Health during the third quarter valued at about $34,000. Quarry LP purchased a new stake in Guardant Health during the second quarter valued at about $44,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Guardant Health during the second quarter valued at about $71,000. Finally, Nisa Investment Advisors LLC lifted its stake in Guardant Health by 168.1% during the third quarter. Nisa Investment Advisors LLC now owns 3,434 shares of the company’s stock valued at $79,000 after buying an additional 2,153 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Insider Buying and Selling

In other Guardant Health news, Director Musa Tariq sold 2,320 shares of the firm’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $35.00, for a total transaction of $81,200.00. Following the transaction, the director now owns 2,676 shares in the company, valued at approximately $93,660. This trade represents a 46.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Meghan V. Joyce sold 2,896 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total value of $86,590.40. Following the transaction, the director now owns 7,648 shares in the company, valued at approximately $228,675.20. This trade represents a 27.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,548 shares of company stock worth $179,782 over the last three months. 5.50% of the stock is currently owned by company insiders.

Guardant Health Stock Performance

Shares of NASDAQ:GH opened at $47.65 on Thursday. Guardant Health, Inc. has a twelve month low of $15.81 and a twelve month high of $49.86. The firm has a market cap of $5.89 billion, a PE ratio of -11.24 and a beta of 1.28. The business has a fifty day moving average of $36.31 and a 200-day moving average of $29.92.

Guardant Health (NASDAQ:GH) last announced its earnings results on Wednesday, November 6th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. The business had revenue of $191.48 million during the quarter, compared to analyst estimates of $170.49 million. During the same quarter last year, the business posted ($0.73) earnings per share. The business’s quarterly revenue was up 33.9% compared to the same quarter last year. On average, analysts anticipate that Guardant Health, Inc. will post -3.44 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on GH shares. Guggenheim reiterated a “buy” rating on shares of Guardant Health in a report on Wednesday, January 22nd. JPMorgan Chase & Co. upped their target price on Guardant Health from $48.00 to $50.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. The Goldman Sachs Group upped their target price on Guardant Health from $36.00 to $49.00 and gave the company a “buy” rating in a report on Tuesday. Leerink Partners dropped their target price on Guardant Health from $60.00 to $50.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Finally, Barclays initiated coverage on Guardant Health in a report on Thursday, January 23rd. They issued an “overweight” rating and a $60.00 target price on the stock. Sixteen research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $42.63.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.